Hong Kong-listed MicroPort Scientific Corporation (MICROPORT) announced that its subsidiary, Suzhou MicroPort Orthopedics Scientific (Group) Co., Ltd., signed a non-binding Letter of Intent on 15 July 2026 with Shanghai-listed Tinavi Medical Technologies Co., Ltd. The document outlines preliminary terms for Tinavi to acquire a controlling equity interest in Shanghai MicroPort Orthopedics Co., Ltd.—the Group’s key international orthopedics platform—through the issuance of new Tinavi shares.
The Target Company, 82.29% owned by Suzhou MicroPort, anchors MICROPORT’s overseas hip and knee joint reconstruction business, with established sales networks across the United States, Japan and Europe. Its flagship medial pivot knee prosthesis reports a 17-year cumulative retention rate of 98.80% and a 95% patient-satisfaction rate (The Knee, 2017).
Tinavi is a mainland China leader in orthopedic surgical robotics, operating the TiRobot series in more than 200 domestic medical institutions and supporting over 160,000 surgeries as of end-Q1 2026. Management expects the proposed transaction to combine Tinavi’s robotics expertise with the Target Group’s joint replacement portfolio and global distribution channels, seeking to accelerate long-term growth for both businesses.
Key terms—exact equity percentage, valuation, share-issue price and other conditions—remain under negotiation and will be finalized in formal agreements. Completion is subject to due diligence, definitive documentation, internal approvals and regulatory clearance under PRC and Hong Kong rules. MICROPORT indicates the deal, if concluded, could constitute a notifiable transaction under Chapter 14 of the Hong Kong Listing Rules.
Shareholders and potential investors are advised that the transaction is at the planning stage and may not proceed. Caution in dealing in MICROPORT shares is recommended until further announcements clarify transaction terms and progress.
Comments